Proactive Investors - Run By Investors For Investors

Narhex Life Sciences commences respiratory illness diagnosis app trials

Narhex Life Sciences commences respiratory illness diagnosis app trials

Narhex Life Sciences (ASX:NLS) acquisition target, ResApp Diagnostics, has enrolled its first patient at Joondalup Health Campus in Western Australia.

The trial will gather data from 150 patients with a variety of respiratory conditions with the aim of further optimising the ResApp algorithms for pneumonia and asthma.

In addition, the trial aims to broaden the validation to other common respiratory conditions such as bronchitis, bronchiolitis and upper respiratory tract conditions.

Preliminary results from this trial are expected within three months.

ResApp is currently finalising ethics approval to commence an additional trial at a second major Australian hospital that will greatly increase the speed in which patient data can be acquired.

The commencement of the trial at Joondalup Health Campus was featured on Channel 7’s Today Tonight on Monday, 23 March 2015.

ResApp, through the exclusive licence it has been granted by the University of Queensland, is developing mobile medical applications for the diagnosis and management of respiratory disease.

Addressable markets for this technology include at-home diagnosis and management of respiratory disease; licensing to large telehealth providers; and working with organisations such as the World Health Organisation to deliver tools for low-cost diagnosis and management of respiratory illness in the developing world.

Cough is the most common single reason for a doctor visit, and in the US, over 100 million primary care physician visits result in diagnosis of a respiratory disease.

According to a recent Rock Health report, US venture capital investment in mHealth for the first half of 2014 represented $2.4 billion, exceeding the total invested in 2013.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full RAP profile View Profile

ResApp Health Ltd Timeline

September 22 2017

Related Articles

Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use